RENB Renovaro Inc.

AI Employees for E-CommerceBeta

Unlock 24/7 fully automated AI staff for your online store. Experience the future of e-commerce operations—no humans required. Limited closed beta access!

Get Early Access →

Subscribe to $RENB

Renovaro Inc.

Subscribe to $RENB

$RENB

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for Renovaro Inc.

Date	Price Target	Rating	Analyst

See more ratings

Renovaro Inc. Press Releases

Fastest customizable press release news feed in the world

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ:POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following t
5/22/25 3:12:39 PM ET
$POAI
$RENB
Industrial Specialties
Health Care
Biotechnology: Pharmaceutical Preparations
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ:POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following t
5/22/25 11:05:00 AM ET
$POAI
$RENB
Industrial Specialties
Health Care
Biotechnology: Pharmaceutical Preparations
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it has launched Augusta, a Precision Neurology Platform for patient stratification, biomarker discovery, drug discovery, and validation. Augusta is focused on neurology where diagnosis and treatment have historically lagged. Built on the company's Renovaro Cube and Elion platforms and recently validated
5/14/25 9:15:00 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center ("Amsterdam UMC") to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement of a promising new approach to disease detection and monitoring. The collaboration will focus on assessing the clinical utility of blood platelet RNA signatures as a powerful biomarker source. This effort will leverage the uniqu
5/13/25 9:15:00 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro's deep learning and ML programs with Nebul's high-performance computing ("HPC") built on the latest platform to accelerate biomarker discovery and next-generation diagnostics. David Weinstein, CEO of Renovaro, stated, "By utilizing Nebul'
4/22/25 9:20:00 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali
4/9/25 9:25:00 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ:POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. ("POI") dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025
4/4/25 9:40:00 AM ET
$POAI
$RENB
Industrial Specialties
Health Care
Biotechnology: Pharmaceutical Preparations
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States Renovaro's Strategic Acquisition of BioSymetrics Vastly Expands Biomarker and Drug Discovery Opportunities and the Development of Diagnostic Applications in Oncology LOS ANGELES, March 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has advanced the first tranche of financing to Predictive Oncology, Inc. (NASDAQ:POAI) to initiate t
3/3/25 9:15:00 AM ET
$POAI
$RENB
Industrial Specialties
Health Care
Biotechnology: Pharmaceutical Preparations
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States Renovaro's recent strategic acquisition of BioSymetrics vastly expands Predictive Oncology's biomarker and drug discovery opportunities and the development of diagnostic applications in oncology Merger expected to enhance shareholder value, accelerate business development efforts and solidify positioning in the capital markets PITTSBURGH, March 03, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today announced that it has received
3/3/25 9:00:00 AM ET
$POAI
$RENB
Industrial Specialties
Health Care
Biotechnology: Pharmaceutical Preparations
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicin
2/26/25 1:25:00 PM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care

Renovaro Inc. Leadership Updates

Live Leadership Updates

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali
4/9/25 9:25:00 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicin
2/26/25 1:25:00 PM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Renovaro Appoints Nathen Fuentes as Chief Financial Officer
Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh. Nathen Fuentes comes to Renovaro as a senior biotechnology and specialty healthcare financial executive with a depth and breadth of functional and industry experiences based upon progressively senior strategic, operational and financial l
1/7/25 9:15:00 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Renovaro Issues Shareholder Letter and Provides Corporate Update
Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive analysis of both businesses and development of a 100-day plan of action has already turned up some hidden value in both businesses and is helping us understand key areas of the business we need to for
1/7/25 9:15:00 AM ET
$POAI
$RENB
Industrial Specialties
Health Care
Biotechnology: Pharmaceutical Preparations
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV
Current Renovaro Chairman to Lead Subsidiary's Development Program and Commercialization LOS ANGELES and AMSTERDAM, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced Chairman of the Board, Maurice van Tilburg, has been appointed as Chief Executive Officer of its subsidiary GEDi Cube BV (a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies) DBA RenovaroCube. Maurice van Tilburg has held several senior positions in the Financial Services industry and Tech enterprises combining general management, technology, operational service delivery,
12/30/24 9:00:05 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Renovaro Announces Strategic Restructuring and Leadership Transition
Supermajority of Shareholders Support Appointment of New CEO and the Replacement of Entire Board of Directors with Full Five-Member SlateRealignment of Resources to Optimize and Commercialize RenovaroCube, the Company's Disruptive AI Platform for Multi-omics Diagnostics for Cancer Early Detection and Patient Monitoring from Liquid Biopsies Newly Appointed Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and TreatmentRestructuring to Accelerate Growth, Commercialization, Access to Strategic Capital and Create Long-Term Value for Shareholders LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer
10/16/24 9:28:06 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (NASDAQ:RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer. Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these lim
4/30/24 11:00:00 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and mon
4/24/24 9:00:00 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro's quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies. Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an
4/18/24 8:45:00 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.Cyclomics' 4th generation liquid biopsy genomics platform is the first truly "Omni-Omic" blood test ready for AI application.GEDiCube's award-winning AI is developing high-performance biomarker panels for 13 different cancers. GEDiCube's partnership with NVIDIA's Inception program will help expand to multi-modal capabilities by adding imaging. The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response
2/15/24 9:25:00 AM ET
$RENB
Biotechnology: Pharmaceutical Preparations
Health Care

Renovaro Inc.

Recent Analyst Ratings for Renovaro Inc.

Renovaro Inc.

Recent Analyst Ratings for Renovaro Inc.

Renovaro Inc. SEC Filings

SEC Form 10-Q filed by Renovaro Inc.

Renovaro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Renovaro Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events

Renovaro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Renovaro Inc.

Amendment: SEC Form 10-Q/A filed by Renovaro Inc.

Amendment: SEC Form 10-K/A filed by Renovaro Inc.

Amendment: SEC Form 10-Q/A filed by Renovaro Inc.

Renovaro Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

SEC Form NT 10-Q filed by Renovaro Inc.

Renovaro Inc. Press Releases

Fastest customizable press release news feed in the world

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Renovaro Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner William Anderson Wittekind disposed of 350,000 shares, decreasing direct ownership by 9% to 3,353,878 units (SEC Form 4)

Director Van Tilburg Maurice was granted 250,000 shares (SEC Form 4)

SEC Form 4 filed by Chief Financial Officer Fuentes Nathen

SEC Form 3 filed by new insider Fuentes Nathen

SEC Form 4 filed by Director Collins Mark Anthony

SEC Form 4 filed by Director Calder Douglas W

SEC Form 4 filed by Interim CFO Tarsh Simon

SEC Form 4 filed by Director Mcnulty James A

SEC Form 3 filed by new insider Van Tilburg Maurice

SEC Form 3 filed by new insider Collins Mark Anthony

Renovaro Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

SEC Form SC 13D/A filed by Renovaro Inc. (Amendment)

SEC Form SC 13D/A filed by Renovaro Inc. (Amendment)

SEC Form SC 13G/A filed by Renovaro Inc. (Amendment)

Renovaro Inc. Leadership Updates

Live Leadership Updates

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Renovaro Issues Shareholder Letter and Provides Corporate Update

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Renovaro Announces Strategic Restructuring and Leadership Transition

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership

Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace